

Research article

Open Access

# Quantification of *SLIT-ROBO* transcripts in hepatocellular carcinoma reveals two groups of genes with coordinate expression

Mehmet Ender Avci, Ozlen Konu and Tamer Yagci\*

Address: Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey

Email: Mehmet Ender Avci - aender@bilkent.edu.tr; Ozlen Konu - konu@fen.bilkent.edu.tr; Tamer Yagci\* - tyagci@fen.bilkent.edu.tr

\* Corresponding author

Published: 29 December 2008

Received: 14 July 2008

BMC Cancer 2008, 8:392 doi:10.1186/1471-2407-8-392

Accepted: 29 December 2008

This article is available from: <http://www.biomedcentral.com/1471-2407/8/392>

© 2008 Avci et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Abstract

**Background:** SLIT-ROBO families of proteins mediate axon pathfinding and their expression is not solely confined to nervous system. Aberrant expression of *SLIT-ROBO* genes was repeatedly shown in a wide variety of cancers, yet data about their collective behavior in hepatocellular carcinoma (HCC) is missing. Hence, we quantified *SLIT-ROBO* transcripts in HCC cell lines, and in normal and tumor tissues from liver.

**Methods:** Expression of *SLIT-ROBO* family members was quantified by real-time qRT-PCR in 14 HCC cell lines, 8 normal and 35 tumor tissues from the liver. ANOVA and Pearson's correlation analyses were performed in R environment, and different clinicopathological subgroups were pairwise compared in Minitab. Gene expression matrices of cell lines and tissues were analyzed by Mantel's association test.

**Results:** Genewise hierarchical clustering revealed two subgroups with coordinate expression pattern in both the HCC cell lines and tissues: *ROBO1*, *ROBO2*, *SLIT1* in one cluster, and *ROBO4*, *SLIT2*, *SLIT3* in the other, respectively. Moreover, *SLIT-ROBO* expression predicted AFP-dependent subgrouping of HCC cell lines, but not that of liver tissues. *ROBO1* and *ROBO2* were significantly up-regulated, whereas *SLIT3* was significantly down-regulated in cell lines with high-AFP background. When compared to normal liver tissue, *ROBO1* was found to be significantly overexpressed, while *ROBO4* was down-regulated in HCC. We also observed that *ROBO1* and *SLIT2* differentiated histopathological subgroups of liver tissues depending on both tumor staging and differentiation status. However, *ROBO4* could discriminate poorly differentiated HCC from other subgroups.

**Conclusion:** The present study is the first in comprehensive and quantitative evaluation of *SLIT-ROBO* family gene expression in HCC, and suggests that the expression of *SLIT-ROBO* genes is regulated in hepatocarcinogenesis. Our results implicate that *SLIT-ROBO* transcription profile is bimodular in nature, and that each module shows intrinsic variability. We also provide quantitative evidence for potential use of *ROBO1*, *ROBO4* and *SLIT2* for prediction of tumor stage and differentiation status.

## Background

*Drosophila slit* and *roundabout (robo)* genes were identified in genetic screens of mutants for embryonic patterning and commissural axon pathfinding defects [1]. Subsequently, it was shown that SLIT acts as a ligand for ROBO receptor, preventing axons from recrossing the central nervous system (CNS) midline, and that this binding is conserved among vertebrates including mammals [2,3]. In mammals, three *SLIT* (*SLIT1-3*) and four *ROBO* (*ROBO1-4*) genes have been described [4,5].

*SLIT* and *ROBO* genes are mainly expressed in the CNS but there are affirmative data that they are also expressed in non-neuronal tissues, such as mouse lung and kidney [6,7]. Binding of SLIT2 to ROBO1 inhibits CXCL12-induced chemotaxis of leukocytes, T cells and monocytes [8-10]. However, ROBO4 expression has been found to be confined to vasculature and Robo4 signaling modulates endothelial cell migration [11].

On the other hand, like other developmental pathways, aberrant expression of the *SLIT-ROBO* genes has been observed in a wide variety of cancers. Mice with targeted homozygous deletion of first Ig domain of *Robo1/Dutt1* died at birth because of abnormal lung development, and few survivors eventually developed epithelial bronchial hyperplasia [6]. In breast carcinoma tissue samples *ROBO1* was shown to be overexpressed while *SLIT2* induced migration of breast cancer cell lines [12]. *SLIT2-ROBO1* signaling was involved in angiogenesis by increasing microvessel density and tumor mass in a tumor xenograft model [13]. In the same study, *SLIT2* exhibited overexpression in tumor cell lines and primary tumors of a variety of tissues. In contrast, *SLIT2* also was proposed to be a tumor suppressor gene, which was silenced epigenetically in lung, breast, colon cancers and gliomas [14-16]. *SLIT3* was silenced by promoter hypermethylation in gliomas and colorectal cancers [17]. *SLIT1* and *SLIT3* were overexpressed in prostate tumors [18], whereas along with *SLIT2* they were slightly expressed only in poorly differentiated HCC [19]. CXCL12 was reported to activate the migration of human melanoma and breast cancer cells that express CXCR4, ROBO1 and ROBO2, while *SLIT2-ROBO* interaction was demonstrated to inhibit chemotaxis, chemoinvasion and adhesion of breast cancer cells [20]. Furthermore, ROBO4 was overexpressed in tumor endothelial cells in comparison to normal adult endothelial cells [21].

Despite the compiling evidence of *SLIT-ROBO* deregulation in various tumors, only few reports with apparent controversies exist with regard to the expression pattern of these genes in hepatocellular carcinoma (HCC). The overexpression of ROBO1 in HCC was recently reported and this receptor was proposed as an HCC marker in humans

[19]. In contrast, another study reported that *Robo1* heterozygous mice developed spontaneous HCC tumors [22]. It was shown by immunohistochemical staining that SLIT2 protein also was present in HCC tumor sections [13]. Moreover, karyotyping analyses of HCC do not reveal any chromosomal gains or losses associated with *SLIT-ROBO* genes [23,24]. Therefore, in this study, we quantified *SLIT1*, *SLIT2*, *SLIT3*, *ROBO1*, *ROBO2* and *ROBO4* transcripts in HCC cell lines and tissues. We observed that *SLIT-ROBO* genes could be partitioned into two main clusters based on their expression in either the HCC cell lines or tissues. *SLIT-ROBO* expression also clustered the HCC cell lines in two groups according to their *AFP* expression pattern. In liver tissues, differential expression of *ROBO1*, *ROBO4* and *SLIT2* was found to be associated with clinicopathological parameters such as tumor staging and differentiation. Herein, we describe a comprehensive *SLIT-ROBO* expression signature in HCC.

## Methods

### HCC Cell Lines and Tissues

13 hepatoma and 1 hepatoblastoma (HepG2) cell lines were included in the study and cultured as previously described [25]. Focus, Hep40, Hep3B, Hep3B-TR, HepG2, HUH7, Mahlavu, PLC/PRF/5, SK Hep1 cells were cultured in low-glucose DMEM supplemented with 10% FBS, 100 U/ml Penicillin-Streptomycin, and 0.1 mM non-essential amino acids (HyClone, Utah, USA). SNU387, SNU398, SNU423, SNU449, SNU475 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 U/ml Penicillin-Streptomycin, 0.1 mM non-essential amino acids (HyClone, Utah, USA). TissueScan Liver Cancer Tissue qPCR Arrays, each containing 40 liver tumor and 8 tumor-adjacent normal tissue cDNAs, were purchased from Origene Technologies, (Rockville, MD, USA). 5 non-HCC tumor tissues consisting of 3 cholangiocarcinomas, 1 nodular hyperplasia and 1 liver adenoma were excluded from the present study. Clinicopathological characteristics of the tissues were presented in Additional file 1.

### Primers

PCR primers for human *SLITs*, *ROBO1* and *ROBO2* were previously described [18]. Human *ROBO3*, *ROBO4* and *AFP* (*alpha-fetoprotein*) primers were designed using Primer3 and targeting exon-exon junctions in order to prevent amplification of possible contaminating genomic DNA [26]. Primer sequences were as follows: *ROBO3* forward 5'-CAGTGTCCGATGGAAGAAGG-3' and reverse 5'-GTCCATCTCCTGCACATTGG-3', *ROBO4* forward 5'-GACACTTGGCGTTCCACCTC-3' and reverse 5'-AGAGCAAGGAGCGACGACAG-3', *AFP* forward 5'-AAATGCGTTTCTCGTTGCTT-3' and reverse 5'-CCAACACCAGGGTTTACTGG-3'. Primer pair for the housekeeping gene *GAPDH* (*glyceraldehyde-3-phosphate dehydrogenase*) was described before [27]. *ACTB* (*beta-*

actin) primer pair was supplemented in TissueScan Liver Cancer Tissue qPCR Array 1 (Origene Technologies, Rockville, MD, USA).

### RNA Isolation and cDNA Synthesis

Cell lines were grown to confluency in 100 mm dishes. Total RNA was extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany) according to manufacturer's instructions. cDNA was synthesized with random hexamers from 1 µg of total RNA using DyNAmo™ cDNA Synthesis Kit (Finnzymes, Espoo, Finland).

### Real-time Quantitative RT-PCR Analyses of HCC Cell Lines

In cell lines and tissues, the relative expression ratio (R) of *SLIT-ROBO* and *AFP* transcripts (target gene) was measured based on a modified  $\Delta\Delta Ct$  formula [28] and normalized to *GAPDH* or *ACTB* (reference gene). In

$$R = (E_{target})^{\Delta Ct_{target}(\text{control-sample})} / (E_{ref})^{\Delta Ct_{ref}(\text{control-sample})}$$

formula,  $E_{target}$  and  $E_{ref}$  reflect PCR efficiencies of the primers for target genes and reference genes, respectively. PCR efficiency values for each primer pair was obtained by constructing a standard curve using threshold cycle (Ct) values derived from 6 data points, corresponding to 2-fold decrements of an original cDNA stock (duplicates were prepared for each dilution). The slope of the resulting curve was used to calculate the E value of primer pairs according to  $E = 2^{-1/\text{slope}}$  formula. PCR efficiencies of the genes ranged between 1.9 and 2.0.  $\Delta Ct$  was the difference between the Ct values of controls and samples.

In cell lines, *GAPDH* was the reference gene.  $\Delta Ct$  values were obtained by subtracting Ct values of individual genes (sample) from the average Ct value of all cell lines for that gene (control). All reactions were performed in duplicates and repeated at least twice using different batches of RNA preparations. Relative expression tables were established by representing  $\Delta\Delta Ct$  values in log2 base, and in all subsequent analyses these values were used.

Quantitative expression analyses were performed using DyNAmo™ HS SYBR® Green qPCR Kit (Finnzymes, Espoo, Finland) on an iCycler iQ real-time PCR detection system (Bio-Rad, Richmond, CA). The PCR reaction was set according to the manufacturer's recommendations. Briefly for 1× reaction; 10 µl of 2× SYBR Green PCR Master Mix, 10 µM forward and reverse primers, and 1 µl of template cDNA were mixed in a total volume of 20 µl. After an initial 15 minutes of denaturation at 95°C, thermal cycling was performed at 94°C for 30 sec, 60–62°C for 30 sec (optimized for each primer pair), 72°C for 30 sec for a total of 50 cycles and a final extension step at 72°C for

10 min. In order to validate the production of a single target-specific PCR product, the amplification was followed by a melt curve protocol with an initial step at 55°C for 30 sec and 80 repeats of 0.5°C increments with 15 sec dwell time, from 55°C to 95°C.

### Real-time Quantitative RT-PCR Analyses of HCC Tissues

The expression of *SLIT-ROBO* and *AFP* genes in HCC was analyzed using a 96-well plate format TissueScan Liver Cancer Tissue qPCR Array 1 (Origene Technologies, Rockville, MD), which contained tissue cDNAs normalized against beta-actin. Real-time PCR protocol was applied as described by the manufacturer. Briefly, 30 µl of reaction mix containing 15 µl 2× SYBR Green PCR Master Mix and 10 µM forward and reverse primers was directly added to PCR-plate wells. Plate was placed on ice for 15 min for cDNAs to dissolve, and thermal cycling was performed according to above mentioned protocol. For each gene, mean Ct value of the normal tissue cDNAs was set as the control group and relative quantitative expression values were calculated with the  $\Delta\Delta Ct$  formula and were represented in log2 base by taking the *ACTB* Ct values as reference.

### Statistical Analysis

Using one-way ANOVA in R, mean expression levels of each gene were compared between high and low *AFP* expressing groups of HCC cell lines; and also between normal and tumor tissues of liver with respect to differentiation or stage [29]. Pairwise comparisons were made using Fisher's multiple pairwise comparison method in Minitab® 13.20 Statistical Software (Minitab Inc. 2000). Furthermore, two-way hierarchical cluster analysis was used to group cell lines and liver tissues with respect to the *SLIT-ROBO* expression patterns using Cluster and TreeView [30]. Pairwise correlations between *SLIT-ROBO* gene expression levels were calculated using Pearson's correlation coefficient. Moreover, a Mantel's association test was applied to compare cell line and tissue correlation matrices [29].

### Results


#### QRT-PCR analyses reveal an association between *SLIT-ROBO* and *AFP* expression in HCC cell lines

We first investigated by RT-PCR the presence of *SLIT-ROBO* transcripts in 13 HCC and 1 hepatoblastoma cell lines. All genes were expressed at levels varying from none to strong after 40 cycles of amplification (Additional file 2). Since HCC cell lines were previously reported to cluster in two main molecular subtypes in terms of their *alpha-fetoprotein* (*AFP*) expression [31] we quantified *SLIT-ROBO* gene expression along with *AFP* transcript levels.

In our first set of qRT-PCR experiments, cell lines with fibroblastoid morphology, including Focus, Mahlavu, SK

Hep1, SNU387, SNU398, SNU423, SNU449 and SNU475, displayed low-*AFP* expression, while *AFP* was found to be overexpressed in epitheloid Hep40, Hep3B, Hep3B-TR, HepG2, HUH7 and PLC/PRF/5 cells (Figure 1). Second, we quantified *SLIT-ROBO* transcripts. *ROBO2* and *SLIT1* expression were up-regulated in high-*AFP* group of cells, except HepG2, which underexpressed *ROBO2* (Additional file 3). On the other hand, both genes were found to be overexpressed in SNU398, one of the low-*AFP* group of cell lines. *SLIT3* transcript levels sharply contrasted those of *ROBO2* and *SLIT1*. Except SNU398, increased *SLIT3* expression was found among low-*AFP* expressing group of cell lines, and also in high-*AFP* expressing Hep40 cell line. Interestingly, widespread expression of *ROBO1* transcripts that we observed in RT-PCR turned out to be enhanced in cell lines with high-*AFP* background (Additional file 2 and 3). *ROBO4* and *SLIT2* transcript levels remained variable among HCC cell lines and no phenotype-based association could be observed for these genes. Our attempts to calculate PCR efficiency with two different *ROBO3* primer pairs failed, and we discontinued qRT-PCR analysis of this gene.

A significant association of gene expression was found among *SLIT-ROBO* family genes and *AFP* based on Pearson's pairwise correlation coefficients (Table 1). In particular, expressions of *ROBO1* and *SLIT3* were significantly correlated with that of *AFP*, in a positive and negative manner, respectively.



**Figure 1**  
**Quantification of AFP transcript levels reveals two groups in HCC cell lines.** GAPDH normalized *AFP* expression was quantified by real-time RT-PCR and expression values of individual cell lines are calculated relative to the Ct average of all cell lines, and represented in log<sub>2</sub> base. Samples were run in duplicates and the data are representative of two independent experiments.

**Cluster analyses identify two subgroups in HCC cell lines with respect to SLIT-ROBO expression levels**

Hierarchical clustering was performed in order to understand whether *SLIT-ROBO* expression predicts *AFP*-dependent grouping of HCC cell lines. In fact, in terms of *SLIT-ROBO* expression, low-*AFP* expressing SNU449, SNU423, SNU475, Mahlavu, SK Hep1, SNU387, and Focus cells grouped together (Group I), while high-*AFP* expressing HepG2, PLC/PRF/5, HUH7, Hep3B-TR, HEP-3B and Hep40 cell lines (Group II) clustered separately from the first group (Figure 2). Exceptionally, SNU398 cell line displayed a *SLIT-ROBO* expression pattern concordant with Group II despite its low-*AFP* background. The expression of *AFP* significantly differed between the two groups ( $p = 0.0001$ ): Mean expression of *AFP* in Group I and Group II cells was  $-4.65 \pm 2.75$  and  $6.20 \pm 4.68$ , respectively.

Hierarchical clustering analysis also revealed a genewise segregation of *SLIT-ROBO* genes. Coordinate expression was observed in two main clusters, one of which grouping together *ROBO1*, *ROBO2* and *SLIT1*, and the other *ROBO4*, *SLIT2*, and *SLIT3*, respectively (Figure 2). We also performed one-way ANOVA to identify individual *SLIT-ROBO* genes, which significantly separate HCC cell lines with high- and low-*AFP* expression. We validated that *ROBO1* and *ROBO2* expression were up-regulated in high-*AFP* group ( $p = 6.7 \times 10^{-4}$  and  $p = 0.013$ , respectively). Mean expression of *ROBO1* in Group I was  $-1.73 \pm 2.15$  while in Group II cells increased to  $2.37 \pm 0.48$ . Similarly, *ROBO2* mean expression values were found as  $-2.37 \pm 3.31$  and  $3.11 \pm 3.73$ , for Group I and Group II, respectively. In sharp contrast, *SLIT3* was overexpressed in cell lines with low-*AFP* profile (Mean<sub>GroupI</sub> =  $3.28 \pm 4.43$ , Mean<sub>GroupII</sub> =  $-4.24 \pm 4.06$ ;  $p = 6.9 \times 10^{-3}$ ).

**SLIT-ROBO family expression profile in liver tissues correlates with that in HCC cell lines**

Next, we addressed the question of whether our cell line data translate to *in vivo* conditions. To this end, we quantified the expression of *SLIT-ROBO* and *AFP* genes using cDNAs of 8 tumor-adjacent normal and 35 tumor tissues (Additional file 4). Accordingly, only *ROBO1* was found to be significantly overexpressed in tumor tissues (Mean<sub>Normal</sub> =  $0 \pm 0.63$ , Mean<sub>Tumor</sub> =  $1.57 \pm 1.63$ ;  $p = 0.011$ ). We also observed a down-regulated *ROBO4* expression in tumor tissues with a p-value near significance (Mean<sub>Normal</sub> =  $0 \pm 1.03$ , Mean<sub>Tumor</sub> =  $-0.89 \pm 1.30$ ;  $p = 0.079$ ). *AFP* displayed a highly variable expression, yet it was overexpressed in more than half of the tumors (18/35) (Additional file 4).

Hierarchical clustering grouped *SLIT-ROBO* genes in a similar manner as in cell lines. *ROBO1*, *ROBO2* and *SLIT1* clustered together, whereas *ROBO4*, *SLIT2* and *SLIT3*

**Table 1: Genewise correlation of *SLIT-ROBO* and *AFP* genes in HCC cell lines**

Gene	<i>ROBO1</i>	<i>ROBO2</i>	<i>ROBO4</i>	<i>SLIT1</i>	<i>SLIT2</i>	<i>SLIT3</i>	<i>AFP</i>
<i>ROBO1</i>	1						
<i>ROBO2</i>	0.6060*	1					
<i>ROBO4</i>	-0.2721	-0.2653	1				
<i>SLIT1</i>	0.4027	0.7623*	-0.3288	1			
<i>SLIT2</i>	0.1241	0.1891	0.5143	-0.0039	1		
<i>SLIT3</i>	-0.5698*	-0.6072*	0.3681	-0.5451*	-0.1003	1	
<i>AFP</i>	0.6533*	0.5108	-0.3016	0.4579	0.3544	-0.6605*	1

\*:  $p < 0.05$ 

formed another cluster (Figure 3). Two main clusters appeared among tissue samples; however, no significant association of clusters was found with differentiation state or staging of tumors (Wilcoxon rank sum test) and *AFP* expression (one-way ANOVA).

Expression correlation amongst individual *SLIT-ROBO* and *AFP* genes in liver tissues was analyzed by Pearson's correlation analysis in R (Table 2). Accordingly, expression of *ROBO1* in HCC samples was positively correlated with that of *AFP* whereas *ROBO4* and *AFP* were inversely correlated in terms of their expression. Mantel's permutation test, performed to compare gene expression correlation matrices of cell lines and tissues (described in Table 1 and Table 2, respectively), indicated that gene-to-gene correlation patterns in both sample groups were significantly associated ( $r = 0.49$ ;  $p < 0.02$ ).

#### ***ROBO1* expression differentiates normal tissues from tumors with respect to both stage and differentiation status**


We also performed one-way ANOVA followed by Fisher's multiple pairwise comparisons in order to explore whether gene expression characteristics of *SLIT-ROBO* family members discriminate among liver tissues with respect to differentiation status and staging of the samples. The tissue samples lacking stage or differentiation information in the pathological reports were left out of analysis. With these criteria, a total of 43 liver tissue samples for stage and of 38 tissue samples for differentiation status were analyzed. According to one-way ANOVA, *ROBO1* differentiated liver tissue samples on both the stage ( $p = 0.018$ ) and differentiation status ( $p = 0.031$ ) dependent manner (Figure 4A, B). *ROBO4* expression significantly discriminated tissues only with respect to their

differentiation status ( $p = 0.039$ ) (Figure 4C). Moreover, Fisher's pairwise comparison analyses revealed that *ROBO1*, *SLIT2* and *ROBO4* significantly discriminated between different histopathological subgroups both in terms of differentiation status and/or tumor staging (Table 3).

#### **Discussion**

HCC remains the fifth most common cancer worldwide and is at the third rank in cancer-caused deaths. The prognosis of patients is generally very poor with a 5-year relative survival of only 7% [32]. The elucidation of molecular mechanisms governing hepatocarcinogenesis is therefore of high priority not only for the better understanding of the disease, but also to develop more effective therapies. To achieve this goal, functional genomics studies could provide valuable information with regard to genes differentially expressed between HCC and normal liver. A collective analysis of expression signature of *SLIT-ROBO* family genes has not been assessed yet in liver tumor. Here, we showed the co-regulation of *SLIT-ROBO* genes in HCC. In both the HCC cell lines and liver tissues, *ROBO1*, *ROBO2*, *SLIT1*, and *ROBO4*, *SLIT2*, *SLIT3* showed coordinate expression as two distinct modules, yet displaying high variability at gene level within each module. Additionally, *SLIT-ROBO* expression was able to predict *AFP* status of HCC cell lines, and thereby establishing two groups with low- and high-*AFP* expressions.

Except *ROBO3*, all genes were found to be expressed at different levels in our analyses. A preferential up- and down-regulation of *SLIT-ROBO* genes occurred depending on the *AFP* expression status of HCC cell lines. *ROBO1*, *ROBO2* and to a lesser extent *SLIT1* were overexpressed, whereas *SLIT3* was underexpressed in high-*AFP*




**Figure 2**  
**SLIT-ROBO expression establishes two groups, which predict AFP expression levels in HCC cell lines.** The means of normalized expression values of individual *SLIT-ROBO* genes in each cell line were used to establish the hierarchical clustering in Cluster program, and the results were visualized as a heatmap by TreeView. Overexpression and underexpression of individual genes relative to Ct average of all cell lines are represented by red and green colors, respectively. Upper single-row heatmap displays the average expression of all six genes across all cell lines. The tree at the top of the heatmap represents samplewise clustering. Based on their *AFP* expression levels, HCC cell lines are represented in two main subgroups indicated as Group I (low-*AFP*) and Group II (high-*AFP*) cells. The tree on the left of the heatmap (pink) represents genewise clustering.

group. *ROBO4* also tended to be down-regulated in this group. However, *SLIT2* was expressed in most of the cell lines, regardless of the *AFP* expression status.

We also quantified *SLIT-ROBO* expression in 8 tumor-adjacent normal liver tissues and 35 HCC tumors. We found that genewise clustering observed in HCC cell lines

were conserved in tissues: *ROBO1*, *ROBO2*, *SLIT1* and *ROBO4*, *SLIT2*, *SLIT3* were coordinately expressed, respectively. We also noticed two main subgroups in tissue samples but the observed *AFP* dependent subgrouping in HCC cell lines did not translate into the tissue analysis, except that *AFP* and *ROBO1* expression was significantly correlated in both HCC cell lines and tissues. This discrep-



**Figure 3**  
**Genewise clustering of SLIT-ROBO genes in HCC cell lines translates into liver tissues.** The normalized expression values of individual SLIT-ROBO genes in liver tissue samples (n = 43) were used to establish the hierarchical clustering in Cluster program and the results were visualized as a heatmap by TreeView. Overexpression and underexpression of individual genes relative to Ct average of normal tissues (n = 8) are represented by red and green colors, respectively. Upper single-row heatmap displays the average expression of all six genes across all tissues. The tree at the top of the heatmap represents sample-wise clustering, and the tree on the left of the heatmap (pink) represents genewise clustering. T1-35: tumors; N1-8: normal tissues; 0: stage 0 (non-tumor); 1, 2, 3A, 4: stage 1, stage 2, stage 3A, stage 4 HCC, respectively; N: tumor-adjacent normal tissue; W: well-differentiated; M: moderately differentiated; P: poorly differentiated; N/A: not-assigned.


ancy might be partly due to the heterogeneity of tissues. HCC cell lines were more homogenous when compared to tissue samples, which may contain stromal cells, endothelial cells, immune cells or any other tumor infiltrating cells. Moreover, our normal liver samples were tumor-adjacent tissues, which may harbor genetic changes of tumor microenvironment, and therefore may not reveal the actual molecular characteristics of a tumor-free normal liver.

ROBO1 transcript was present in all cell lines that were examined and it was significantly up-regulated in the analyzed HCC tissues, in which its overexpression culminated in later stages and as tumors progress to a less differentiated state. These data were in agreement with a recent report that demonstrated ROBO1 as an HCC antigen and proposing it as both a diagnostic marker and therapeutic target for HCC [19]. SLIT2 was present in most of the tumor tissues and HCC cell lines although at variable levels. Such variability might explain the clustering of SLIT2

**Table 2: Genewise correlation of SLIT-ROBO and AFP genes in liver tissues**

Gene	ROBO1	ROBO2	ROBO4	SLIT1	SLIT2	SLIT3	AFP
ROBO1	1						
ROBO2	0.1835	1					
ROBO4	-0.1879	-0.2134	1				
SLIT1	0.0298	0.002	-0.3793*	1			
SLIT2	-0.3679*	-0.0078	0.3432*	-0.1389	1		
SLIT3	-0.0973	-0.0027	0.2596	-0.0965	0.6844***	1	
AFP	0.3679*	0.2324	-0.3699*	0.0924	-0.0769	-0.1638	1

\*\*\*: p < 0.001; \*: p < 0.05



**Figure 4**  
**ROBO1 and ROBO4 expression discriminate between different stage and differentiation groups of liver tissues.** Expression values of *SLIT-ROBO* genes were compared using one-way ANOVA in liver tissue samples that are stratified according to their stages and differentiation status and represented as boxplots. (A) *ROBO1* significantly differentiates one staging group from the others ( $p = 0.018$ ). (B) The expression of *ROBO1* also discriminates between different differentiation status of liver tissues ( $p = 0.031$ ). (C) *ROBO4* also significantly separates one differentiation group among all ( $p = 0.039$ ).

in a different group than *ROBO1* and *ROBO2*, yet it is likely to be the main ligand for ROBO receptors. Nevertheless, this does not exclude interactions between other SLIT and ROBO members, nor it does the possible ligand-independent activities of ROBO receptors in HCC. Additionally, *SLIT2* and *ROBO1* were both upregulated in HCCs with advanced stages and poor differentiation status (Figure 3 and Table 3). These findings also are in agreement with the expression of SLITs specifically in poorly differentiated HCCs [19]. Furthermore, in a tumor xenograft model, *SLIT2-ROBO1* signaling was shown to

have a role in angiogenesis, which supports tumor growth and metastasis [13].

Although *ROBO4* was shown to be specific to vasculature [11], we observed varying levels of *ROBO4* transcript in HCC cell lines. The *ROBO4* transcripts in these cells might be partly explained by the presence of side population cells with stem cell characteristics that express markers of the vascular endothelium [33]. One may also consider a possible regulation of *ROBO4* expression in liver tumors. In tissue expression analyses, we found that *ROBO4*

**Table 3: Differentially expressed SLIT-ROBO genes between histopathological subgroups of liver tissues**

Stage	n	Mean expression (SE)	Differentially expressed gene*
0	8	0 (0.22)	ROBO1
2	11	2.37 (0.41)	
0	8	0 (0.22)	ROBO1
3	13	1.43 (0.57)	
1	9	0.79 (0.33)	ROBO1
2	11	2.37 (0.41)	
2	11	-2.29 (1.15)	SLIT2
3	13	-0.96 (0.44)	
Differentiation state	n	Mean expression (SE)	Differentially expressed gene*
Normal	8	0 (0.22)	ROBO1
Moderate	16	1.89 (0.44)	
Normal	8	0 (0.22)	ROBO1
Poor	6	1.84 (0.60)	
Normal	8	0 (0.36)	ROBO4
Poor	6	-2.02 (0.80)	
Well	8	-0.60 (0.43)	ROBO4
Poor	6	-2.02 (0.80)	
Moderate	16	-0.66 (0.25)	ROBO4
Poor	6	-2.02 (0.80)	
Moderate	16	-1.28 (0.78)	SLIT2
Poor	6	1.01 (0.88)	

\* Pairs of stage and differentiation subgroups were compared in Fisher's pairwise comparison analysis and only the genes that significantly discriminate between subgroups were represented ( $p < 0.05$ ). SE: standard error.

expression is significantly down-regulated in poorly differentiated tumors, indicating that ROBO4 function is not essential for the maintenance of tumor at this step of hepatocarcinogenesis. In fact, recent findings indicated that SLIT2-ROBO4 interactions inhibited angiogenesis [34].

It is very likely that SLIT2-ROBO1-ROBO4 might contribute to some of the variability associated with the differentiation status of HCC while expression of ROBO1 and SLIT2 also helps explain the stage differences in this cancer. However, the expression variability is high among liver tumors suggesting that a combinatorial code with a possibility of ligand redundancy might be at work in hepatocellular carcinoma, which prompts further functional studies that include knock-down and overexpression.

A global gene expression analysis by microarray technology in 19 HCC cell lines revealed two molecular subtypes depending on their AFP expression level [31]. Of 14 HCC cell lines that we studied, 13 were included in that study and the SLIT-ROBO dependent subgrouping in our analysis was parallel to the AFP subgrouping previously observed, verifying the reliability of our cell line panel. ROBO1 and SLIT3 were the genes that were most significantly correlated with AFP expression in a positive and negative manner, respectively. Genes regulating extracellular matrix establishment or remodeling and cell adhesion were shown to be differentially expressed between the HCC cell line subgroups [31]. Cells that were defined to be more metastatic and motile correspond to cell lines that cluster as Group I in our study. Given the important roles of SLIT-ROBO associated signaling molecules like ENA, ABL, and several GTPase activating proteins in

cytoskeletal reorganization and cell motility [35,36], the connection between SLIT-ROBO signaling and HCC tumor cell invasion and metastasis remains to be further described.

## Conclusion

Here, we defined the overexpression of *ROBO1* and the variable expression of other *SLIT-ROBO* family members in HCC. Especially, downregulation of *ROBO4* and upregulation of *SLIT2* mark late stage and poorly differentiated HCCs. We have also shown that the collective expression of these genes occurs in a coordinated fashion in two main groups suggesting that SLIT-ROBO signaling is modular in nature, and that each module shows intrinsic variability. Our results help increase our understanding of pathological expression pattern of *SLIT-ROBO* family in HCC with potential for diagnostic applications. Elucidation of the mechanisms acting on the transcriptional regulation of SLIT-ROBO signaling pathway, such as alternative splicing, copy number variability and ligand/receptor redundancy in both HCC and other pathophysiological contexts will contribute to a better understanding of hepatocarcinogenesis.

## Abbreviations

HCC: hepatocellular carcinoma; *ROBO*: roundabout; *AFP*: alpha-fetoprotein; *GAPDH*: glyceraldehyde-3-phosphate dehydrogenase; *ACTB*: beta-actin.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

MEA designed the primers, performed RT-PCR and real-time PCR experiments, and contributed to statistical analyses. OK participated in the design of the study, supervised the statistical analyses, and helped draft the manuscript. TY designed and coordinated the study, and finalized the manuscript. All authors read and approved the final manuscript.

## Additional material

### Additional file 1

*Clinicopathological characteristics of normal liver and HCC samples. This table gives Diagnosis/Histology, stage and differentiation information for normal and tumor tissues used in the study.*

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2407-8-392-S1.pdf>]

### Additional file 2

*SLIT-ROBO genes are expressed in HCC cell lines at varying levels. Agarose gel electrophoresis image of SLIT-ROBO transcripts in 14 HCC cell lines after 40 cycles of RT-PCR amplification.*

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2407-8-392-S2.tiff>]

### Additional file 3

*Relative expression of SLIT-ROBO and AFP genes in HCC cell lines. This table lists the  $\Delta\Delta Ct$  values in log<sub>2</sub> base for SLIT-ROBO and AFP transcripts in 14 HCC cell lines used in the study.*

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2407-8-392-S3.pdf>]

### Additional file 4

*Relative expression of SLIT-ROBO and AFP genes in normal liver and HCC samples. This table lists the  $\Delta\Delta Ct$  values in log<sub>2</sub> base for SLIT-ROBO and AFP transcripts in 8 normal liver and 35 HCC samples used in the study.*

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2407-8-392-S4.pdf>]

## Acknowledgements

The authors are grateful to Dr. E. Oztas for his help in image processing. This work was supported by grant I04S243 from the Scientific and Technological Research Council of Turkey (TUBITAK), and funds from Bilkent University.

## References

- Dickson BJ, Gilestro GF: **Regulation of commissural axon path-finding by slit and its Robo receptors.** *Annu Rev Cell Dev Biol* 2006, **22**:651-675.
- Kidd T, Bland KS, Goodman CS: **Slit is the midline repellent for the robo receptor in Drosophila.** *Cell* 1999, **96**:785-794.
- Brose K, Bland KS, Wang KH, Arnott D, Henzel W, Goodman CS, Tessier-Lavigne M, Kidd T: **Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance.** *Cell* 1999, **96**:795-806.
- Brose K, Tessier-Lavigne M: **Slit proteins: key regulators of axon guidance, axonal branching, and cell migration.** *Curr Opin Neurobiol* 2000, **10**:95-102.
- Huminiecki L, Gorn M, Suchting S, Poulsom R, Bicknell R: **Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis.** *Genomics* 2002, **79**:547-552.
- Xian J, Clark KJ, Fordham R, Pannell R, Rabbitts TH, Rabbitts PH: **Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the *Dutt1/Robo1* gene.** *Proc Natl Acad Sci USA* 2001, **98**:15062-15066.
- Griesshammer U, Le M, Plump AS, Wang F, Tessier-Lavigne M, Martin GR: **SLIT2-mediated ROBO2 signaling restricts kidney induction to a single site.** *Dev Cell* 2004, **6**:709-717.
- Wu JY, Feng L, Park HT, Havlioglu N, Wen L, Tang H, Bacon KB, Jiang Z, Zhang X, Rao Y: **The neuronal repellent Slit inhibits leukocyte chemotaxis induced by chemotactic factors.** *Nature* 2001, **410**:948-952.
- Prasad A, Qamri Z, Wu J, Ganju RK: **Slit-2/Robo-1 modulates the CXCL12/CXCR4-induced chemotaxis of T cells.** *J Leukoc Biol* 2007, **82**:465-476.
- Guan H, Zu G, Xie Y, Tang H, Johnson M, Xu X, Kevil C, Xiong WC, Elmets C, Rao Y, Wu JY, Xu H: **Neuronal repellent Slit2 inhibits**

- dendritic cell migration and the development of immune responses. *J Immunol* 2003, **171**:6519-6526.
11. Park KW, Morrison CM, Sorensen LK, Jones CA, Rao Y, Chien CB, Wu JY, Urness LD, Li DY: **Robo4 is a vascular-specific receptor that inhibits endothelial migration.** *Dev Biol* 2003, **261**:251-267.
  12. Schmid BC, Reznicek GA, Fabjani G, Yoneda T, Leodolter S, Zeillinger R: **The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells.** *Breast Cancer Res Treat* 2007, **106**:333-342.
  13. Wang B, Xiao Y, Ding BB, Zhang N, Yuan X, Gui L, Qian KX, Duan S, Chen Z, Rao Y, Geng JG: **Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity.** *Cancer Cell* 2003, **4**:19-29.
  14. Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER, Latif F: **SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.** *Cancer Res* 2002, **62**:5874-5880.
  15. Dallol A, Morton D, Maher ER, Latif F: **SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells.** *Cancer Res* 2003, **63**:1054-1058.
  16. Dallol A, Krex D, Hesson L, Eng C, Maher ER, Latif F: **Frequent epigenetic inactivation of the SLIT2 gene in gliomas.** *Oncogene* 2003, **22**:4611-4616.
  17. Dickinson RE, Dallol A, Bieche I, Krex D, Morton D, Maher ER, Latif F: **Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers.** *Br J Cancer* 2004, **91**:2071-2078.
  18. Latif A, Chene L, Cochant-Priollet B, Mangin P, Fournier G, Berthon P, Cussenot O: **Quantification of expression of netrins, slits and their receptors in human prostate tumors.** *Int J Cancer* 2003, **103**:306-315.
  19. Ito H, Funahashi S, Yamauchi N, Shibahara J, Midorikawa Y, Kawai S, Kinoshita Y, Watanabe A, Hippo Y, Ohtomo T, Iwanari H, Nakajima A, Makuuchi M, Fukayama M, Hirata Y, Hamakubo T, Kodama T, Tsuchiya M, Aburatani H: **Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target.** *Clin Cancer Res* 2006, **12**:3257-3264.
  20. Prasad A, Fernandis AZ, Rao Y, Ganju RK: **Slit protein-mediated inhibition of CXCR4-induced chemotactic and chemoinvasive signaling pathways in breast cancer cells.** *J Biol Chem* 2004, **279**:9115-9124.
  21. Seth P, Lin Y, Hanai J, Shivalingappa V, Duyao MP, Sukhatme VP: **Magic roundabout, a tumor endothelial marker: expression and signaling.** *Biochem Biophys Res Commun* 2005, **332**:533-541.
  22. Xian J, Aitchison A, Bobrow L, Corbett G, Pannell R, Rabbitts T, Rabbitts P: **Targeted disruption of the 3p12 gene, Dutt1/Robo1, predisposes mice to lung adenocarcinomas and lymphomas with methylation of the gene promoter.** *Cancer Res* 2004, **64**:6432-6437.
  23. Midorikawa Y, Makuuchi M, Tang W, Aburatani H: **Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges.** *World J Gastroenterol* 2007, **13**:1487-1492.
  24. Midorikawa Y, Yamamoto S, Ishikawa S, Kamimura N, Igarashi H, Sugimura H, Makuuchi M, Aburatani H: **Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays.** *Oncogene* 2006, **25**:5581-5590.
  25. Celikkaya H, Ciraci C, Oztas E, Avci ME, Ozturk M, Yagci T: **Immunization with UV-induced apoptotic cells generates monoclonal antibodies against proteins differentially expressed in hepatocellular carcinoma cell lines.** *Hybridoma (Larchmt)* 2007, **26**:55-61.
  26. Rozen S, Skaletsky H: **Primer3 on the WWW for general users and for biologist programmers.** *Methods Mol Biol* 2000, **132**:365-386.
  27. Sayan AE, Sayan BS, Findikli N, Ozturk M: **Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells.** *Oncogene* 2001, **20**:5111-5117.
  28. Pfaffl MW: **A new mathematical model for relative quantification in real-time RT-PCR.** *Nucleic Acids Res* 2001, **29**:e45.
  29. R Development Core Team: **R: A Language and Environment for Statistical Computing.** R Foundation for Statistical Computing Vienna, Austria ISBN 3-900051-07-0 2005.
  30. Eisen MB, Spellman PT, Brown PO, Botstein D: **Cluster analysis and display of genome-wide expression patterns.** *Proc Natl Acad Sci USA* 1998, **95**:14863-14868.
  31. Lee JS, Thorgeirsson SS: **Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer.** *Hepatology* 2002, **35**:1134-1143.
  32. Bosch FX, Ribes J, Diaz M, Cleries R: **Primary liver cancer: worldwide incidence and trends.** *Gastroenterology* 2004, **127**:S5-S16.
  33. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY: **Identification and characterization of tumorigenic liver cancer stem/progenitor cells.** *Gastroenterology* 2007, **132**:2542-2556.
  34. Jones CA, London NR, Chen H, Park KW, Sauvaget D, Stockton RA, Wythe JD, Suh W, Larrieu-Lahargue F, Mukoyama YS, Lindblom P, Seth P, Frias A, Nishiya N, Ginsberg MH, Gerhardt H, Zhang K, Li DY: **Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability.** *Nat Med* 2008, **14**:448-453.
  35. Bashaw GJ, Kidd T, Murray D, Pawson T, Goodman CS: **Repulsive axon guidance: Abelson and Enabled play opposing roles downstream of the roundabout receptor.** *Cell* 2000, **101**:703-715.
  36. Wong K, Ren XR, Huang YZ, Xie Y, Liu G, Saito H, Tang H, Wen L, Brady-Kalnay SM, Mei L, Wu JY, Xiong WC, Rao Y: **Signal transduction in neuronal migration: roles of GTPase activating proteins and the small GTPase Cdc42 in the Slit-Robo pathway.** *Cell* 2001, **107**:209-221.

### Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2407/8/392/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

